FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550620007> ?p ?o ?g. }

• W2550620007 endingPage "2075" @default.
• W2550620007 startingPage "2064" @default.
• W2550620007 abstract "Nasopharyngeal carcinoma (NPC) is highly incident in southern China. Metastasis is the major cause of death in NPC patients. Concurrent chemoradiotherapy (CCRT) has been accepted as standard in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma (NPC). However, induction chemotherapy (IC) also has benefits in this disease, especially in the patients with certain high-risk factors such as bulky and/or extensive nodal disease. It has been presented that adding IC to CCRT might be a reasonable approach and need more work to confirm. The optimal chemotherapeutic regimen combined with radiotherapy has not been determined so far. It is important to explore high effective and low toxic chemotherapy for the patients. In the multicenter prospective study, 223 patients with locoregionally advanced untreated NPC were randomized into experimental group and control group. The patients received two cycles of induction chemotherapy (IC) with docetaxel (DOC) plus nedaplatin (NDP) in experimental group every 3 weeks, followed by IMRT concurrent with weekly NDP for six cycles, and NDP was replaced by cisplatin (CDDP) in control group. More patients in experimental group could receive full courses of IC and concurrent chemoradiotherapy (CCRT) (P=0.013). There was no significant difference between the two groups in the percentage of reduction of GTVnx and GTVnd after IC (P=0.207 and P=0.107) and CR rate three months after completion of chemoradiotherapy (P=0.565 and P=0.738). With a mean follow-up of 35.1 months, no statistically significant difference in the 3-year OS, LRFS, RRFS, DMFS, and PFS was found. During IC, more patients suffered vomiting in control group (P=0.001). During CCRT, grade 3/4 neutropenia/thrombocytopenia were more common in experimental group (P=0.028 and P=0.035); whereas, severe anemia and vomiting were more common in control group (P=0.0001 and P=0.023). In conclusions, patients with locoregionally advanced NPC showed good tolerance and compliance with a manageable toxicity profile to the regimen of IC with DOC plus NDP followed by concomitant NDP and IMRT, which is as effective as the regimen of DOC plus CDDP as IC followed by concomitant CDDP and IMRT. This trial is registered at ClinicalTrials.gov (NCT 01479504)." @default.
• W2550620007 created "2016-11-30" @default.
• W2550620007 creator A5005539004 @default.
• W2550620007 creator A5006083516 @default.
• W2550620007 creator A5007631869 @default.
• W2550620007 creator A5009777873 @default.
• W2550620007 creator A5012488008 @default.
• W2550620007 creator A5012628375 @default.
• W2550620007 creator A5013446276 @default.
• W2550620007 creator A5020885511 @default.
• W2550620007 creator A5035164451 @default.
• W2550620007 creator A5059798382 @default.
• W2550620007 date "2016-01-01" @default.
• W2550620007 modified "2023-09-26" @default.
• W2550620007 title "Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial." @default.
• W2550620007 cites W1482683008 @default.
• W2550620007 cites W1554801388 @default.
• W2550620007 cites W1765858588 @default.
• W2550620007 cites W1965631966 @default.
• W2550620007 cites W1976270947 @default.
• W2550620007 cites W1992300472 @default.
• W2550620007 cites W1994039305 @default.
• W2550620007 cites W1998253030 @default.
• W2550620007 cites W2005374110 @default.
• W2550620007 cites W2024922069 @default.
• W2550620007 cites W2078682598 @default.
• W2550620007 cites W2092572151 @default.
• W2550620007 cites W2104431898 @default.
• W2550620007 cites W2105051592 @default.
• W2550620007 cites W2125919881 @default.
• W2550620007 cites W2135556091 @default.
• W2550620007 cites W2145844073 @default.
• W2550620007 cites W2146701819 @default.
• W2550620007 cites W2146900413 @default.
• W2550620007 cites W2158776902 @default.
• W2550620007 cites W2160982012 @default.
• W2550620007 cites W2403503144 @default.
• W2550620007 cites W2438319535 @default.
• W2550620007 cites W92388963 @default.
• W2550620007 cites W2013726379 @default.
• W2550620007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5043115" @default.
• W2550620007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27725911" @default.
• W2550620007 hasPublicationYear "2016" @default.
• W2550620007 type Work @default.
• W2550620007 sameAs 2550620007 @default.
• W2550620007 citedByCount "13" @default.
• W2550620007 countsByYear W25506200072017 @default.
• W2550620007 countsByYear W25506200072018 @default.
• W2550620007 countsByYear W25506200072019 @default.
• W2550620007 countsByYear W25506200072020 @default.
• W2550620007 countsByYear W25506200072021 @default.
• W2550620007 countsByYear W25506200072022 @default.
• W2550620007 crossrefType "journal-article" @default.
• W2550620007 hasAuthorship W2550620007A5005539004 @default.
• W2550620007 hasAuthorship W2550620007A5006083516 @default.
• W2550620007 hasAuthorship W2550620007A5007631869 @default.
• W2550620007 hasAuthorship W2550620007A5009777873 @default.
• W2550620007 hasAuthorship W2550620007A5012488008 @default.
• W2550620007 hasAuthorship W2550620007A5012628375 @default.
• W2550620007 hasAuthorship W2550620007A5013446276 @default.
• W2550620007 hasAuthorship W2550620007A5020885511 @default.
• W2550620007 hasAuthorship W2550620007A5035164451 @default.
• W2550620007 hasAuthorship W2550620007A5059798382 @default.
• W2550620007 hasConcept C126322002 @default.
• W2550620007 hasConcept C143998085 @default.
• W2550620007 hasConcept C2776611710 @default.
• W2550620007 hasConcept C2776694085 @default.
• W2550620007 hasConcept C2778203143 @default.
• W2550620007 hasConcept C2778239845 @default.
• W2550620007 hasConcept C2778424827 @default.
• W2550620007 hasConcept C2778997737 @default.
• W2550620007 hasConcept C2781190966 @default.
• W2550620007 hasConcept C2781413609 @default.
• W2550620007 hasConcept C509974204 @default.
• W2550620007 hasConcept C71924100 @default.
• W2550620007 hasConceptScore W2550620007C126322002 @default.
• W2550620007 hasConceptScore W2550620007C143998085 @default.
• W2550620007 hasConceptScore W2550620007C2776611710 @default.
• W2550620007 hasConceptScore W2550620007C2776694085 @default.
• W2550620007 hasConceptScore W2550620007C2778203143 @default.
• W2550620007 hasConceptScore W2550620007C2778239845 @default.
• W2550620007 hasConceptScore W2550620007C2778424827 @default.
• W2550620007 hasConceptScore W2550620007C2778997737 @default.
• W2550620007 hasConceptScore W2550620007C2781190966 @default.
• W2550620007 hasConceptScore W2550620007C2781413609 @default.
• W2550620007 hasConceptScore W2550620007C509974204 @default.
• W2550620007 hasConceptScore W2550620007C71924100 @default.
• W2550620007 hasIssue "9" @default.
• W2550620007 hasLocation W25506200071 @default.
• W2550620007 hasOpenAccess W2550620007 @default.
• W2550620007 hasPrimaryLocation W25506200071 @default.
• W2550620007 hasRelatedWork W2043367053 @default.
• W2550620007 hasRelatedWork W2061800353 @default.
• W2550620007 hasRelatedWork W2286844863 @default.
• W2550620007 hasRelatedWork W2364176225 @default.
• W2550620007 hasRelatedWork W2464098867 @default.
• W2550620007 hasRelatedWork W2550620007 @default.
• W2550620007 hasRelatedWork W2901278141 @default.

• next